SCIO 323

Drug Profile

SCIO 323

Alternative Names: SCIO-323

Latest Information Update: 26 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scios
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 26 May 2010 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
  • 05 May 2003 Scios has been acquired by Johnson & Johnson
  • 10 Feb 2003 SCIO 323 is available for licensing (http://www.sciosinc.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top